Discovery of BPR2-D2 compound in inhibiting Chikungunya viral RNA synthesis by replicon systems
Biomedical Journal · 2026
DOI: 10.1016/j.bj.2026.100949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Journal, 2026. Verfasst von Yi-Ju Hsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Chikungunya virus, RNA, Viral, Virus Replication, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Linkou Chang Gung Memorial Hospital, Ministry of Education, National Science and Technology Council.
Abstract (Originalsprache)
Chikungunya virus (CHIKV), an alphavirus in the Togaviridae family, is transmitted to humans through mosquito bites and can lead to severe complications in newborns and elders. Its RNA genome functions as mRNA to produce viral nonstructural proteins, which assemble into replication complex for synthesizing new viral genomic and subgenomic RNA within the cytoplasm. Previous studies have established a CHIKV replicon system, that can express CHIKV replication complex from viral genomic RNA and an eGFP reporter from subgenomic RNA, to study viral RNA replication and screen antivirals against the CHIKV RNA replication. Additionally, researchers have discovered that BPR2-D2, which is classified to furanocoumarin, exhibits potential as a broad-spectrum antiviral drug. In this research, we applied the replicon system to evaluate the antiviral activity of BPR2-D2 against CHIKV RNA replication. The effective concentration was 10.47 ± 0.02297 nM for inhibiting 50 % of CHIKV genomic RNA replication with high selective index. Moreover, we validated the antiviral effect of BPR2-D2 with the authentic infection of Sindbis virus, which is also an arthritogenic alphavirus. The molecular docking analysis was applied to suggest possible targets of BPR2-D2 among CHIKV nonstructural proteins. Taken together, this research demonstrated that BPR2-D2 can be a promising antiviral against CHIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- International Master Degree Program for Molecular Medicine in Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Institute of Prevention Medicine, National Defense Medical University, Taipei, Taiwan.
- Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan; International Master Degree Program for Molecular Medicine in Emerging Viral Infections, College o…
Förderung
- Linkou Chang Gung Memorial Hospital
- Ministry of Education
- National Science and Technology Council
Zitieren
APA
Hsu, Y. J., Phan, T. T., Lin, H. C., Chiao, D. J., Kuo, S. C., Lin, S. J., & Kuo, R. L. (2026). Discovery of BPR2-D2 compound in inhibiting Chikungunya viral RNA synthesis by replicon systems. Biomedical Journal. https://doi.org/10.1016/j.bj.2026.100949
Vancouver
Hsu YJ, Phan TT, Lin HC, Chiao DJ, Kuo SC, Lin SJ, et al. Discovery of BPR2-D2 compound in inhibiting Chikungunya viral RNA synthesis by replicon systems. Biomedical Journal. 2026. doi:10.1016/j.bj.2026.100949
BibTeX
@article{Hsu2026,
author = {Hsu, Yi-Ju and Phan, Tram-Anh Thi and Lin, Hui-Chung and Chiao, Der-Jiang and Kuo, Szu-Cheng and Lin, Syh-Jae and Kuo, Rei-Lin},
title = {Discovery of BPR2-D2 compound in inhibiting Chikungunya viral RNA synthesis by replicon systems},
journal = {Biomedical Journal},
year = {2026},
doi = {10.1016/j.bj.2026.100949}
}
EUVIMED